Actively Recruiting
Universal CAR-T Cells Targeting Multiple Myeloma
Led by Shenzhen Geno-Immune Medical Institute · Updated on 2026-04-24
20
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T cells in the body.
CONDITIONS
Official Title
Universal CAR-T Cells Targeting Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with confirmed multiple myeloma who failed curative treatments including stem cell transplantation
- Incomplete remission after at least two prior therapy regimens
- High-risk multiple myeloma in first or second remission and not eligible for stem cell transplant due to age or other health issues
- Less than 1 year between last chemotherapy and disease progression
- Relapsed after prior stem cell transplant with residual disease and not eligible for allogeneic transplant
- Residual disease after primary therapy and not eligible for autologous stem cell transplant
- Expected survival longer than 12 weeks
- Creatinine level below 2.5 mg/dl
- ALT and AST levels less than three times the normal limit
- Bilirubin level below 2.0 mg/dl
- Any relapse after prior stem cell transplant is eligible
- Adequate venous access for apheresis and no contraindications for leukapheresis
- Signed voluntary informed consent
You will not qualify if you...
- Pregnant or breastfeeding women
- Uncontrolled active infections
- Active hepatitis B or hepatitis C infection
- Current use of systemic steroids (inhaled steroids allowed)
- Previous related CAR-T cell therapy
- Any uncontrolled active medical disorder that would prevent participation
- HIV infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shenzhen Geno-Immune Medical Institute
Shenzhen, Guangdong, China, 518000
Actively Recruiting
Research Team
L
Lung-Ji Chang, PhD
CONTACT
Y
Ying Deng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here